Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 360

1.

Perspectives From Masters in Rheumatology and Autoimmunity: Can We Get Closer to a Cure for Rheumatoid Arthritis?

Feldmann M, Maini RN.

Arthritis Rheumatol. 2015 Sep;67(9):2283-91. doi: 10.1002/art.39269. No abstract available.

2.

Anti-TNF therapy, from rationale to standard of care: what lessons has it taught us?

Feldmann M, Maini RN.

J Immunol. 2010 Jul 15;185(2):791-4. doi: 10.4049/jimmunol.1090051.

3.

Anti-TNF therapy from the bench to the clinic: a paradigm of translational research.

Maini RN.

Clin Med (Lond). 2010 Apr;10(2):161-2. No abstract available.

4.

Introducing Arthritis Research & Therapy's 10th anniversary issue, 'The Scientific Basis of Rheumatology: A Decade of Progress'.

Hrynaszkiewicz I, Lipsky PE, Maini RN.

Arthritis Res Ther. 2008;10(5):119. doi: 10.1186/ar2522. Epub 2008 Oct 10. No abstract available.

5.

Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade.

Smolen JS, Han C, van der Heijde DM, Emery P, Bathon JM, Keystone E, Maini RN, Kalden JR, Aletaha D, Baker D, Han J, Bala M, St Clair EW; Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) Study Group.

Ann Rheum Dis. 2009 Jun;68(6):823-7. doi: 10.1136/ard.2008.090019. Epub 2008 Jul 1. Erratum in: Ann Rheum Dis. 2011 Aug;70(8):1519.

PMID:
18593759
6.

Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha.

Elliot MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katasikis P, Brennan FM, Bijl H, Ghrayeb J, Woody JN.

Arthritis Rheum. 2008 Feb;58(2 Suppl):S92-S101. doi: 10.1002/art.23362.

7.

The pitfalls in the development of biologic therapy.

Maini RN, Feldmann M.

Nat Clin Pract Rheumatol. 2007 Jan;3(1):1. No abstract available.

PMID:
17202998
8.

Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate.

Maini RN, Taylor PC, Szechinski J, Pavelka K, Bröll J, Balint G, Emery P, Raemen F, Petersen J, Smolen J, Thomson D, Kishimoto T; CHARISMA Study Group.

Arthritis Rheum. 2006 Sep;54(9):2817-29. Erratum in: Arthritis Rheum. 2008 Mar;58(3):887.

9.

Interleukin-6: a new therapeutic target.

Smolen JS, Maini RN.

Arthritis Res Ther. 2006;8 Suppl 2:S5. Epub 2006 Jul 28. Review. Erratum in: Arthritis Res Ther. 2006;8(6):407.

10.

Infliximab treatment maintains employability in patients with early rheumatoid arthritis.

Smolen JS, Han C, van der Heijde D, Emery P, Bathon JM, Keystone E, Kalden JR, Schiff M, Bala M, Baker D, Han J, Maini RN, St Clair EW.

Arthritis Rheum. 2006 Mar;54(3):716-22.

11.

Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial.

Smolen JS, Van Der Heijde DM, St Clair EW, Emery P, Bathon JM, Keystone E, Maini RN, Kalden JR, Schiff M, Baker D, Han C, Han J, Bala M; Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) Study Group.

Arthritis Rheum. 2006 Mar;54(3):702-10.

12.
13.

Anti-TNF therapy: where have we got to in 2005?

Feldmann M, Brennan FM, Foxwell BM, Taylor PC, Williams RO, Maini RN.

J Autoimmun. 2005;25 Suppl:26-8. Epub 2005 Nov 2. Review.

PMID:
16260118
16.

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial.

St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, Keystone E, Schiff M, Kalden JR, Wang B, Dewoody K, Weiss R, Baker D; Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group.

Arthritis Rheum. 2004 Nov;50(11):3432-43.

17.

Association between baseline radiographic damage and improvement in physical function after treatment of patients with rheumatoid arthritis.

Breedveld FC, Han C, Bala M, van der Heijde D, Baker D, Kavanaugh AF, Maini RN, Lipsky PE.

Ann Rheum Dis. 2005 Jan;64(1):52-5. Epub 2004 Jul 29.

18.

Current and new antitumor necrosis factor agents in perspective.

Maini RN.

Arthritis Res Ther. 2004;6 Suppl 2:S1-2. Epub 2004 Jun 21. Review. No abstract available.

19.

The transfer of a laboratory based hypothesis to a clinically useful therapy: the development of anti-TNF therapy of rheumatoid arthritis.

Feldmann M, Brennan FM, Williams RO, Woody JN, Maini RN.

Best Pract Res Clin Rheumatol. 2004 Feb;18(1):59-80. Review.

PMID:
15123038
20.

Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis.

Taylor PC, Steuer A, Gruber J, Cosgrove DO, Blomley MJ, Marsters PA, Wagner CL, McClinton C, Maini RN.

Arthritis Rheum. 2004 Apr;50(4):1107-16.

21.

Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate.

Maini RN, Breedveld FC, Kalden JR, Smolen JS, Furst D, Weisman MH, St Clair EW, Keenan GF, van der Heijde D, Marsters PA, Lipsky PE; Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

Arthritis Rheum. 2004 Apr;50(4):1051-65.

22.

Anti-TNFalpha therapy of rheumatoid arthritis: what can we learn about chronic disease?

Feldmann M, Brennan FM, Paleolog E, Cope A, Taylor P, Williams R, Woody J, Maini RN.

Novartis Found Symp. 2004;256:53-69; discussion 69-73, 106-11, 266-9. Review.

PMID:
15027483
23.

Infliximab in active early rheumatoid arthritis.

Breedveld FC, Emery P, Keystone E, Patel K, Furst DE, Kalden JR, St Clair EW, Weisman M, Smolen J, Lipsky PE, Maini RN.

Ann Rheum Dis. 2004 Feb;63(2):149-55.

24.

A critical evaluation of enzyme immunoassay kits for detection of antinuclear autoantibodies of defined specificities. III. Comparative performance characteristics of academic and manufacturers' laboratories.

Fritzler MJ, Wiik A, Tan EM, Smolen JS, McDougal JS, Chan EK, Gordon TP, Hardin JA, Kalden JR, Lahita RG, Maini RN, Reeves WH, Rothfield NF, Takasaki Y, Wilson M, Byrd MG, Slivka L, Koziol JA.

J Rheumatol. 2003 Nov;30(11):2374-81.

PMID:
14677180
25.
26.

Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade.

Wagner CL, Schantz A, Barnathan E, Olson A, Mascelli MA, Ford J, Damaraju L, Schaible T, Maini RN, Tcheng JE.

Dev Biol (Basel). 2003;112:37-53.

PMID:
12762503
27.

Blocking tumor necrosis factor inhibits radiographic damage even in patients who show minimal or no clinical improvement: comment on the concise communication by Boers.

Lipsky PE, Felson DT, Maini RN.

Arthritis Rheum. 2002 Oct;46(10):2817-8; author reply 2718-21. No abstract available.

28.

Cytokines and anti-cytokine biologicals in autoimmunity: present and future.

Andreakos ET, Foxwell BM, Brennan FM, Maini RN, Feldmann M.

Cytokine Growth Factor Rev. 2002 Aug-Oct;13(4-5):299-313. Review.

PMID:
12220545
29.

How does infliximab work in rheumatoid arthritis?

Maini RN, Feldmann M.

Arthritis Res. 2002;4 Suppl 2:S22-8. Epub 2002 Mar 27. Review.

30.

Polymorphism in the immunoglobulin VH gene V1-69 affects susceptibility to rheumatoid arthritis in subjects lacking the HLA-DRB1 shared epitope.

Vencovský J, Zd'árský E, Moyes SP, Hajeer A, Ruzicková S, Cimburek Z, Ollier WE, Maini RN, Mageed RA.

Rheumatology (Oxford). 2002 Apr;41(4):401-10.

PMID:
11961170
31.

Discovery of TNF-alpha as a therapeutic target in rheumatoid arthritis: preclinical and clinical studies.

Feldmann M, Maini RN.

Joint Bone Spine. 2002 Jan;69(1):12-8. Review.

PMID:
11858351
32.

Inflammation is preceded by tumor necrosis factor-dependent infiltration of mesenchymal cells in experimental arthritis.

Marinova-Mutafchieva L, Williams RO, Funa K, Maini RN, Zvaifler NJ.

Arthritis Rheum. 2002 Feb;46(2):507-13.

33.

A critical evaluation of enzyme immunoassay kits for detection of antinuclear autoantibodies of defined specificities. II. Potential for quantitation of antibody content.

Tan EM, Smolen JS, McDougal JS, Fritzler MJ, Gordon T, Hardin JA, Kalden JR, Lahita RG, Maini RN, Reeves WH, Rothfield NF, Takasaki Y, Wiik A, Wilson M, Koziol JA.

J Rheumatol. 2002 Jan;29(1):68-74.

PMID:
11824974
34.

The role of TNF alpha and IL-1 in rheumatoid arthritis.

Feldmann M, Brennan FM, Foxwell BM, Maini RN.

Curr Dir Autoimmun. 2001;3:188-99. Review. No abstract available.

PMID:
11791466
35.

Anti-TNF alpha therapy in rheumatoid arthritis--current and future directions.

Taylor PC, Williams RO, Maini RN.

Curr Dir Autoimmun. 2000;2:83-102. Review. No abstract available.

PMID:
11791460
36.

Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis.

Ballara S, Taylor PC, Reusch P, Marmé D, Feldmann M, Maini RN, Paleolog EM.

Arthritis Rheum. 2001 Sep;44(9):2055-64.

37.

Immunotherapy for rheumatoid arthritis.

Taylor PC, Williams RO, Maini RN.

Curr Opin Immunol. 2001 Oct;13(5):611-6. Review.

PMID:
11544014
38.

Cytokine blockade in rheumatoid arthritis.

Feldmann M, Maini RN, Bondeson J, Taylor P, Foxwell BM, Brennan FM.

Adv Exp Med Biol. 2001;490:119-27. Review.

PMID:
11505970
39.
41.

Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?

Feldmann M, Maini RN.

Annu Rev Immunol. 2001;19:163-96. Review.

PMID:
11244034
42.

The Arthritis Research non-peer-review depository.

Lipsky PE, Maini RN.

Arthritis Res. 2000;2(1):1. No abstract available.

43.

Insights into the pathogenesis of rheumatoid arthritis from application of anti-TNF therapy.

Maini RN, Taylor PC, Paleolog E, Charles P, Ballara S, Brennan FM, Feldmann M.

Nihon Rinsho Meneki Gakkai Kaishi. 2000 Dec;23(6):487-9. No abstract available.

PMID:
11210727
44.

Evaluation of TNF-alpha and IL-1 blockade in collagen-induced arthritis and comparison with combined anti-TNF-alpha/anti-CD4 therapy.

Williams RO, Marinova-Mutafchieva L, Feldmann M, Maini RN.

J Immunol. 2000 Dec 15;165(12):7240-5.

45.

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN; Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

N Engl J Med. 2000 Nov 30;343(22):1594-602.

46.

Arthritis Research: more than a journal (http://arthritis-research.com).

Lipsky PE, Maini RN.

Arthritis Res. 1999;1(1):1. Epub 1999 Oct 26. Review. No abstract available.

47.

Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis.

Ulfgren AK, Andersson U, Engström M, Klareskog L, Maini RN, Taylor PC.

Arthritis Rheum. 2000 Nov;43(11):2391-6.

49.

Mesenchymal precursor cells in the blood of normal individuals.

Zvaifler NJ, Marinova-Mutafchieva L, Adams G, Edwards CJ, Moss J, Burger JA, Maini RN.

Arthritis Res. 2000;2(6):477-88. Epub 2000 Aug 31.

50.

Future prospects for anti-cytokine treatment.

Feldmann M, Miotla J, Paleolog E, Williams R, Malfait AM, Taylor P, Brennan FM, Maini RN.

Ann Rheum Dis. 2000 Nov;59 Suppl 1:i119-22. Review.

Supplemental Content

Loading ...
Support Center